The information provided herein is for reference only and is not to be relied upon as making any representation as to the efficacy of any particular formulations
Most patients start on a three-month supply and reassess at that point
Global Reach and Expanding Indications Though currently approved for type 2 diabetes, Tirzepatide is undergoing additional studies for obesity treatment in non-diabetic individuals, as well as cardiovascular outcome trials
The most common problems in those trials were gastrointestinal (nausea, diarrhoea, constipation and vomiting), along with an unusual skin-sensitivity effect
This patient received Lemon Bottle injections for their facial area, reducing the unwanted fat deposits in their mid-face and lower-face regions
Chelsea Hutch, University of Michigan, United States Updates Copyright 2022 Shao, Tian, Yang, Hu, Zhu and Shu